In conclusion, our results suggest that, in patients with breast cancer and HER-2 gene amplification, the use of BiotHER as primary Ab in IHC procedures has the potential to further improve the definition of the target population for Trastuzumab-based treatment. This evidence concerns the gene ERBB2 and breast carcinoma.